BAFNAPHARM Intraday Analysis...

BAFNAPHARM Share Price

Open 28.05 Change Price %
High 29.00 1 Day -0.05 -0.18
Low 28.05 1 Week 0.20 0.71
Close 28.50 1 Month 3.85 15.62
Volume 18611 1 Year -2.25 -7.32
52 Week High 35.95
52 Week Low 22.40
BAFNAPHARM Important Levels
Resistance 2 29.38
Resistance 1 29.02
Pivot 28.52
Support 1 27.98
Support 2 27.62
NSE INDIA Most Active Stocks
JPASSOCIAT 26.60 15.40%
GVKPIL 10.00 19.76%
SINTEX 37.35 -1.32%
GMRINFRA 18.00 1.12%
SUZLON 19.15 3.51%
UNITECH 8.45 -1.17%
IDEA 91.95 -3.26%
IFCI 27.55 4.95%
RENUKA 19.40 17.22%
STRTECH 222.80 7.53%
More..
NSE INDIA Top Gainers Stocks
SPCENET 0.20 33.33%
TIPSINDLTD 79.20 20.00%
GVKPIL 10.00 19.76%
RENUKA 19.40 17.22%
TARAJEWELS 32.05 16.76%
NAKODA 0.35 16.67%
ARCOTECH 98.20 16.08%
SIGNET 10.65 15.76%
JPASSOCIAT 26.60 15.40%
LYKALABS 61.25 15.35%
More..
NSE INDIA Top Losers Stocks
LCCINFOTEC 0.20 -20.00%
SERVALL 2.55 -10.53%
MVL 0.50 -9.09%
MVL 0.50 -9.09%
ANKITMETAL 1.30 -7.14%
JVLAGRO 25.05 -7.05%
DISHTV 78.10 -6.02%
NUCLEUS 289.55 -5.90%
COUNCODOS 4.00 -5.88%
RSSOFTWARE 78.95 -5.56%
More..

Bafna Pharmaceuticals Limited (NSE: BAFNAPHARM)

BAFNAPHARM Technical Analysis 1.5
As on 21st Jul 2017 BAFNAPHARM Share Price closed @ 28.50 and we RECOMMEND Sell for LONG-TERM with Stoploss of 29.61 & Buy for SHORT-TERM with Stoploss of 26.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
BAFNAPHARM Target for July
1st Target up-side 25.77
2nd Target up-side 27.43
3rd Target up-side 29.09
1st Target down-side 21.03
2nd Target down-side 19.37
3rd Target down-side 17.71
BAFNAPHARM Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 56.41 Sideways
MFI (14) MFI is 73.46 Sideways
CCI (20) CCI is 25.03 Sideways
WILLIAM %R (14) William %R is -40.86 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 26.54
10 Day Avg Volume Traded -33.41 % Less then 10 Day Average Volume
BAFNAPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
BAFNAPHARM Address
BAFNAPHARM
N/A
BAFNAPHARM Latest News
BCCL to invest around $3.2M in Lifezen Healthcare   VC Circle   - 19th Mar 15
Bafna Pharmaceuticals clears renewal audit by MHRA-UK   Equity Bulls   - 04th Mar 15
Bafna Pharma stock rallies 8%   Indiainfoline   - 02nd Mar 15
Strides Arcolab acquires majority stake in Bafna Pharma   Daily News & Analysis   - 22nd Jul 14
Bafna Pharmaceuticals Limited   Moneycontrol.com   - 26th Nov 13
Bafna Pharmaceuticals recommends 6% dividend for 2012-13   Economic Times   - 22nd May 13
Bafna Pharma's Raricap sales double in FY13   Myiris.com   - 10th May 13
Bafna Pharma Obtains Ghana FDA Nod To Market Omeran Capsules   RTT News   - 03rd May 13
Bafna Pharma to focus on haematinic drug mkt   Business Standard (blog)   - 13th Apr 11
Bafna Pharma: Stock provides little incentives   Economic Times   - 04th Apr 11
Interactive Technical Analysis Chart Bafna Pharmaceuticals Limited ( BAFNAPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Bafna Pharmaceuticals Limited
BAFNAPHARM Business Profile
Bafna was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. During the year 1995, Bafna Pharmaceuticals Limited was incorporated and it acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine. Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The current market capitalization stands at Rs 49.07 crore. The company has reported a standalone sales of Rs 46.99 crore and a Net Profit of Rs 1.19 crore for the quarter ended September 2013. The company management includes Bafna Mahaveer Chand - Chairman & Managing Director, Paras Bafna - Whole Time Director, Sunil Bafna - Ind. Non-Executive Director, V Rajamani - Ind. Non-Executive Director, R Dwarakanathan - Ind. Non-Executive Director, Kamlesh Kumar - Ind. Non-Executive Director. The Registered office is at Bafna Towers, New No.68, Old No. 299, Thambu Chetty Street, Chennai (Madras), Tamil Nadu - 600001.